– USA, CA – RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the appointment of Dr. Angie You (Ph.D.) to its board of directors.
“I am delighted to welcome Angie to our board of directors. We have worked together in previous organizations and my admiration for Angie’s talent and diverse skill set has only grown over time. She will be an invaluable resource to RayzeBio as we continue to expand the horizons of the targeted radiopharmaceuticals modality,” said CEO, Dr. Ken Song.
About Dr. Angie You
Dr. You is a seasoned biotechnology executive and was recently CEO of Amunix Pharmaceuticals, Inc., where she orchestrated the sale of the Company to Sanofi for over $1.2 billion. She also serves on the board of ORIC Pharmaceuticals, Inc.
Dr. You joined Amunix Pharmaceuticals as CEO in 2018. Prior to joining Amunix, Dr. You served as chief business & strategy officer and head of commercial at Sierra Oncology (Nasdaq: SRRA), where she led the company’s strategic and transactional business and commercial efforts, including building its robust pipeline through acquisition and licensing of several product assets. Prior to Sierra Oncology, Dr. You served as CBO of Aragon Pharmaceuticals. In previous roles, Dr. You served as CBO at Synosia Therapeutics and Ren Pharmaceuticals. Before joining Ren Pharmaceuticals, Dr. You focused on new company formation at Venrock.
“RayzeBio is at the forefront of advancing the targeted radiopharmaceuticals modality to develop treatment solutions for unmet medical needs in solid tumor indications. I have known Ken for over 20 years and am excited to partner with him, the RayzeBio board, and the management team to support the Company in its ambitious goals,” said Dr. Angie You.
Dr. You earned a Ph.D. in Biochemistry from Harvard University and a B.A. in Chemistry from Harvard College.
About RayzeBio
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020.
For more information : https://rayzebio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
